Characteristics of patients with viremia that did not require additional antiviral therapy
| Patient number . | Indication for transplant . | Conditioning iIntensity and graft . | GVHD prophylaxis . | EBV and CMV serostatus (donor/recipient) . | Viral load prior to VST infusion . | Transplant day at infusion . | Transplant day at first viremia . | Peak viral load by 100 d after transplant . | Viral load at 100 d after transplant . | Transplant day when viremia cleared . | Status at last follow-up . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 | AML | MAC MUD PBSC | CSA, MTX, abatacept | CMV: +/+ EBV: +/+ | N/A | 22 | 26, CMV | 1112 | None | 71 | Alive |
| 6 | MPAL | MAC 9/10 Unrelated PBSC | CSA, MMF, abatacept | CMV: −/+ EBV: +/+ | N/A | 25 | 50, EBV | 7480 | <200 | N/A | Alive, relapse after 16 mo |
| 10 | ALL | MAC 9/10 unrelated BM | CSA, MMF, abatacept | CMV: +/− EBV: +/− | N/A | 22 | 34, BKV | 623 | None | 62 | Alive |
| 12 | MDS | MAC 8/10 Unrelated PBSC | T-cell depletion | CMV: +/+ EBV: +/+ | N/A | 40 | 48, CMV 83, EBV | 2329, CMV 1150, EBV | None | 69, CMV 89, EBV | Dead, relapse, day 494 |
| 14 | FA | MAC MRD PBSC | T-cell depletion | CMV: +/+ EBV: +/+ | N/A | 21 | 45, CMV | 1647 | None | 66 | Alive |
| 15 | MDS | MAC MUD Marrow | CSA, MMF, abatacept | CMV: −/− EBV: +/− | N/A | 28 | 40, BKV 47, EBV | 2742, BK 8456, EBV | None, BK <200, EBV | 92, BKV N/A, EBV | Alive |
| 17 | FA | MAC MUD PBSC | T-cell depletion | CMV: +/− EBV: +/− | N/A | 21 | 45, EBV | 46 751 | 9206 | N/A | Alive |
| 24 | Severe aplastic anemia | RIC MUD PBSC | T-cell depletion | CMV: −/− EBV: +/+ | N/A | 23 | 64, BKV | <500 | None | 74 | Alive |
| 25 | FA | MAC MUD PBSC | T-cell depletion | CMV: −/− EBV: +/+ | BK, 713 | 29 | 19, BKV | 5514 | None | 100 | Alive |
| 29 | ALL | MAC MRD PBSC | CSA, MMF | CMV: +/− EBV: +/+ | N/A | 21 | 48, EBV | 4348 | None | 97 | Alive |
| 30 | ALL | MAC MRD Marrow | CSA, MMF | CMV: +/+ EBV: +/+ | N/A | 23 | 76, EBV 34, BKV | 4039, EBV <500, BKV | <200, EBV None, BKV | N/A, EBV 38, BKV | Alive |
| Patient number . | Indication for transplant . | Conditioning iIntensity and graft . | GVHD prophylaxis . | EBV and CMV serostatus (donor/recipient) . | Viral load prior to VST infusion . | Transplant day at infusion . | Transplant day at first viremia . | Peak viral load by 100 d after transplant . | Viral load at 100 d after transplant . | Transplant day when viremia cleared . | Status at last follow-up . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 | AML | MAC MUD PBSC | CSA, MTX, abatacept | CMV: +/+ EBV: +/+ | N/A | 22 | 26, CMV | 1112 | None | 71 | Alive |
| 6 | MPAL | MAC 9/10 Unrelated PBSC | CSA, MMF, abatacept | CMV: −/+ EBV: +/+ | N/A | 25 | 50, EBV | 7480 | <200 | N/A | Alive, relapse after 16 mo |
| 10 | ALL | MAC 9/10 unrelated BM | CSA, MMF, abatacept | CMV: +/− EBV: +/− | N/A | 22 | 34, BKV | 623 | None | 62 | Alive |
| 12 | MDS | MAC 8/10 Unrelated PBSC | T-cell depletion | CMV: +/+ EBV: +/+ | N/A | 40 | 48, CMV 83, EBV | 2329, CMV 1150, EBV | None | 69, CMV 89, EBV | Dead, relapse, day 494 |
| 14 | FA | MAC MRD PBSC | T-cell depletion | CMV: +/+ EBV: +/+ | N/A | 21 | 45, CMV | 1647 | None | 66 | Alive |
| 15 | MDS | MAC MUD Marrow | CSA, MMF, abatacept | CMV: −/− EBV: +/− | N/A | 28 | 40, BKV 47, EBV | 2742, BK 8456, EBV | None, BK <200, EBV | 92, BKV N/A, EBV | Alive |
| 17 | FA | MAC MUD PBSC | T-cell depletion | CMV: +/− EBV: +/− | N/A | 21 | 45, EBV | 46 751 | 9206 | N/A | Alive |
| 24 | Severe aplastic anemia | RIC MUD PBSC | T-cell depletion | CMV: −/− EBV: +/+ | N/A | 23 | 64, BKV | <500 | None | 74 | Alive |
| 25 | FA | MAC MUD PBSC | T-cell depletion | CMV: −/− EBV: +/+ | BK, 713 | 29 | 19, BKV | 5514 | None | 100 | Alive |
| 29 | ALL | MAC MRD PBSC | CSA, MMF | CMV: +/− EBV: +/+ | N/A | 21 | 48, EBV | 4348 | None | 97 | Alive |
| 30 | ALL | MAC MRD Marrow | CSA, MMF | CMV: +/+ EBV: +/+ | N/A | 23 | 76, EBV 34, BKV | 4039, EBV <500, BKV | <200, EBV None, BKV | N/A, EBV 38, BKV | Alive |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CSA, cyclosporine A; FA, Fanconi anemia; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MPAL, mixed phenotypic acute leukemia; MRD, matched related donor; MTX, methotrexate; MUD, matched unrelated donor; PBSC, peripheral blood stem cell; VST, virus-specific T cell.